Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder

Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen will discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.

Moderator:

Gina Lau, PharmD
Regional Medical Lead, Otsuka Pharmaceutical Development & Commercialization, Inc.

Featuring

  • Christoph Correll, MD

    Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

  • Maxine Chen , PhD

    Director, U.S. Medical Affairs, Otsuka Pharmaceutical Development & Commercialization

  • Gina Lau, PharmD (OPDC)

    Regional Medical Lead

Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen, PhD and Gina Lau, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration

Related Resources

  1. Home
  2. Events
  3. Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder